vs

Side-by-side financial comparison of ARTIVION, INC. (AORT) and GCL Global Holdings Ltd (GCL). Click either name above to swap in a different company.

ARTIVION, INC. is the larger business by last-quarter revenue ($116.0M vs $98.7M, roughly 1.2× GCL Global Holdings Ltd). ARTIVION, INC. runs the higher net margin — 2.1% vs -5.2%, a 7.3% gap on every dollar of revenue. GCL Global Holdings Ltd produced more free cash flow last quarter ($-5.2M vs $-7.9M).

Artivion, Inc. is a distributor of cryogenically preserved human tissues for cardiac and vascular transplant applications and develops medical devices. Among its products are human heart valves, which are treated to remove excess cellular material and antigens, and BioGlue surgical adhesive.

GCL Global Holdings Ltd is a leading clean energy enterprise focusing on R&D, production and operation of photovoltaic products, energy storage systems and low-carbon energy solutions. Its main markets cover Asia, Europe, North America, serving utility, commercial and residential distributed energy users across the globe.

AORT vs GCL — Head-to-Head

Bigger by revenue
AORT
AORT
1.2× larger
AORT
$116.0M
$98.7M
GCL
Higher net margin
AORT
AORT
7.3% more per $
AORT
2.1%
-5.2%
GCL
More free cash flow
GCL
GCL
$2.7M more FCF
GCL
$-5.2M
$-7.9M
AORT

Income Statement — Q4 FY2025 vs Q3 FY2025

Metric
AORT
AORT
GCL
GCL
Revenue
$116.0M
$98.7M
Net Profit
$2.4M
$-5.1M
Gross Margin
63.1%
11.0%
Operating Margin
9.2%
-6.7%
Net Margin
2.1%
-5.2%
Revenue YoY
19.2%
Net Profit YoY
114.7%
EPS (diluted)
$0.06
$-0.04

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
AORT
AORT
GCL
GCL
Q4 25
$116.0M
Q3 25
$113.4M
$98.7M
Q2 25
$113.0M
$142.1M
Q1 25
$99.0M
Q4 24
$97.3M
Q3 24
$95.8M
$36.1M
Q2 24
$98.0M
Q1 24
$97.4M
Net Profit
AORT
AORT
GCL
GCL
Q4 25
$2.4M
Q3 25
$6.5M
$-5.1M
Q2 25
$1.3M
$5.6M
Q1 25
$-505.0K
Q4 24
$-16.5M
Q3 24
$-2.3M
$-1.9M
Q2 24
$-2.1M
Q1 24
$7.5M
Gross Margin
AORT
AORT
GCL
GCL
Q4 25
63.1%
Q3 25
65.6%
11.0%
Q2 25
64.7%
15.0%
Q1 25
64.2%
Q4 24
63.2%
Q3 24
63.7%
16.2%
Q2 24
64.6%
Q1 24
64.6%
Operating Margin
AORT
AORT
GCL
GCL
Q4 25
9.2%
Q3 25
11.1%
-6.7%
Q2 25
7.4%
2.3%
Q1 25
2.2%
Q4 24
2.7%
Q3 24
4.6%
-5.6%
Q2 24
6.6%
Q1 24
26.0%
Net Margin
AORT
AORT
GCL
GCL
Q4 25
2.1%
Q3 25
5.7%
-5.2%
Q2 25
1.2%
3.9%
Q1 25
-0.5%
Q4 24
-16.9%
Q3 24
-2.4%
-5.2%
Q2 24
-2.2%
Q1 24
7.7%
EPS (diluted)
AORT
AORT
GCL
GCL
Q4 25
$0.06
Q3 25
$0.13
$-0.04
Q2 25
$0.03
$0.05
Q1 25
$-0.01
Q4 24
$-0.40
Q3 24
$-0.05
Q2 24
$-0.05
Q1 24
$0.18

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
AORT
AORT
GCL
GCL
Cash + ST InvestmentsLiquidity on hand
$64.9M
$16.6M
Total DebtLower is stronger
$215.1M
$52.0M
Stockholders' EquityBook value
$448.2M
$33.1M
Total Assets
$884.8M
$159.9M
Debt / EquityLower = less leverage
0.48×
1.57×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
AORT
AORT
GCL
GCL
Q4 25
$64.9M
Q3 25
$73.4M
$16.6M
Q2 25
$53.5M
$18.2M
Q1 25
$37.7M
Q4 24
$53.5M
Q3 24
$56.2M
$2.7M
Q2 24
$55.0M
Q1 24
$51.1M
Total Debt
AORT
AORT
GCL
GCL
Q4 25
$215.1M
Q3 25
$214.9M
$52.0M
Q2 25
$215.6M
$11.9M
Q1 25
$314.7M
Q4 24
$314.3M
Q3 24
$314.0M
Q2 24
$313.6M
Q1 24
$313.3M
Stockholders' Equity
AORT
AORT
GCL
GCL
Q4 25
$448.2M
Q3 25
$438.7M
$33.1M
Q2 25
$419.9M
$35.9M
Q1 25
$294.3M
Q4 24
$276.2M
Q3 24
$304.7M
$15.9M
Q2 24
$295.1M
Q1 24
$295.0M
Total Assets
AORT
AORT
GCL
GCL
Q4 25
$884.8M
Q3 25
$857.7M
$159.9M
Q2 25
$838.4M
$101.6M
Q1 25
$791.2M
Q4 24
$789.1M
Q3 24
$803.1M
$49.6M
Q2 24
$789.5M
Q1 24
$784.0M
Debt / Equity
AORT
AORT
GCL
GCL
Q4 25
0.48×
Q3 25
0.49×
1.57×
Q2 25
0.51×
0.33×
Q1 25
1.07×
Q4 24
1.14×
Q3 24
1.03×
Q2 24
1.06×
Q1 24
1.06×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
AORT
AORT
GCL
GCL
Operating Cash FlowLast quarter
$19.6M
$-4.8M
Free Cash FlowOCF − Capex
$-7.9M
$-5.2M
FCF MarginFCF / Revenue
-6.9%
-5.3%
Capex IntensityCapex / Revenue
23.7%
0.4%
Cash ConversionOCF / Net Profit
8.06×
TTM Free Cash FlowTrailing 4 quarters
$839.0K

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
AORT
AORT
GCL
GCL
Q4 25
$19.6M
Q3 25
$22.3M
$-4.8M
Q2 25
$15.0M
$-10.3M
Q1 25
$-17.0M
Q4 24
$10.1M
Q3 24
$11.5M
$6.1M
Q2 24
$6.1M
Q1 24
$-5.5M
Free Cash Flow
AORT
AORT
GCL
GCL
Q4 25
$-7.9M
Q3 25
$17.7M
$-5.2M
Q2 25
$11.7M
$-10.5M
Q1 25
$-20.6M
Q4 24
$8.7M
Q3 24
$7.8M
Q2 24
$3.6M
Q1 24
$-9.1M
FCF Margin
AORT
AORT
GCL
GCL
Q4 25
-6.9%
Q3 25
15.6%
-5.3%
Q2 25
10.4%
-7.4%
Q1 25
-20.8%
Q4 24
9.0%
Q3 24
8.2%
Q2 24
3.7%
Q1 24
-9.3%
Capex Intensity
AORT
AORT
GCL
GCL
Q4 25
23.7%
Q3 25
4.1%
0.4%
Q2 25
2.9%
0.1%
Q1 25
3.7%
Q4 24
1.5%
Q3 24
3.8%
Q2 24
2.6%
Q1 24
3.7%
Cash Conversion
AORT
AORT
GCL
GCL
Q4 25
8.06×
Q3 25
3.42×
Q2 25
11.16×
-1.84×
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
-0.73×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

AORT
AORT

Aortic Stent Grafts$43.3M37%
On X$27.8M24%
Preservation Services$24.1M21%
Surgical Sealants$20.3M18%
Other Products$463.0K0%

GCL
GCL

Segment breakdown not available.

Related Comparisons